BioNTech SE

22UA.F

XETRA

97.7

EUR

+0.30(+0.31%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

BioNTech SE fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

-30.63

Price/Book

1.23

Debt/Equity

1.55%

Return on Equity

-4.04%

Dividend Yield

0.00%

EBITDA

-367100000.00

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	482,325,000	18,976,700,000	17,310,600,000	3,819,000,000	2,751,100,000
Gross Profit	-222,037,000	15,116,000,000	12,778,600,000	3,219,200,000	2,209,800,000
Operating Income	-82,417,000	15,283,800,000	12,642,700,000	690,400,000	-1,314,300,000
Net Income	15,200,000	10,292,500,000	9,434,400,000	930,300,000	-665,300,000
Total Assets	2,318,620,000	15,830,800,000	23,279,100,000	23,006,300,000	22,529,700,000
Total Current Liabilities	606,014,000	3,481,600,000	2,950,600,000	2,070,500,000	2,523,200,000
Total Equity	1,371,846,000	11,893,700,000	20,055,600,000	20,245,900,000	19,411,100,000
Free Cash Flow	-98,920,000	735,700,000	13,214,100,000	4,665,900,000	-244,600,000
Cash from Operations	-13,474,000	889,700,000	13,577,400,000	5,371,400,000	207,700,000
Cash from Investing	-144,848,000	-566,100,000	-35,300,000	-6,954,500,000	-2,081,200,000
Cash from Financing	894,725,000	94,200,000	-1,419,300,000	-778,600,000	-45,900,000
Net Change in Cash	691,060,000	482,500,000	12,182,400,000	-2,211,400,000	-1,901,800,000